title: The characterization, current medications, and promising therapeutics targets for premature ejaculation.
abstract: Premature ejaculation (PE) is the most prevalent male sexual dysfunction. This is associated with negative personal and interpersonal psychological outcomes. The pharmacologic treatment of PE includes the use of antidepressants, local anesthetic agents, and phosphodiesterase type 5 inhibitors. While numerous treatments can control PE, only antidepressants and topical anesthetic creams and sprays have recently been shown to be more effective. This review focuses on the physiology and pharmacology of ejaculation, the pathophysiology of PE and the most effective pharmacological treatment of PE. Pharmacotherapy of PE with off-label short-acting selective serotonin reuptake inhibitors (SSRIs) is common, effective, and safe. Dapoxetine, a SSRI with a short half-life, has been recently evaluated for the treatment of PE by several countries and results are promising. In clinical practice, follow-up side effects are an important part of the management strategy for PE. The understanding of etiology, pathophysiology, and treatment modalities of PE would be beneficial to clinician in helping patients with this disappointing sexual problem.
authors.affiliation: Department of Pharmacology, School of Pharmacy, Ankara University, Ankara, Turkey.|Department of Urology, Tulane University Health Sciences Center, New Orleans, LA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Gur
authors.affiliation: Department of Urology, Tulane University Health Sciences Center, New Orleans, LA, USA.
authors.forename: S C
authors.initials: SC
authors.lastname: Sikka
mesh_terms: D000728:Androgens / Q000378:metabolism; D000779:Anesthetics, Local / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001596:Benzylamines / Q000627:therapeutic use; D004542:Ejaculation / Q000502:physiology*; D004703:Endocrine System / Q000502:physiology*; D006801:Humans; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D061686:Premature Ejaculation / Q000188:drug therapy* / Q000503:physiopathology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000728:Androgens; D000779:Anesthetics, Local; D000928:Antidepressive Agents; D001596:Benzylamines; D009281:Naphthalenes; D058986:Phosphodiesterase 5 Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors; C080598:dapoxetine
keywords: dapoxetine; intravaginal ejaculation latency time; pathophysiology; premature ejaculation; selective serotonin reuptake inhibitors; serotonin